Theratechnologies lands $10M milestone

The FDA has accepted Theratechnologies's NDA for tesamorelin, a treatment for excess abdominal fat in HIV patients with lipodystrophy. The acceptance triggers a $10 million milestone payment from partner EMD Serono as part of their collaboration agreement. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.